PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)

Case Report

Volume 5 Issue 4

Increased Incidence of Shingles Status Post (s/p) Covid 19 in Immunocompetent Patient: Case Report

Meena Bai*, Divya Abraham and Harshidaben Chaudhari

March 25, 2025

View PDF

Abstract

Shingles is a painful skin condition caused by the reactivation of the chickenpox virus, which can pose a greater risk to the elderly and those with a weakened immune system. In adults, the most common risk factors are advanced age, stress, other infections (such as AIDS or COVID-19), and immunosuppression. HZ reactivation has recently been observed following vaccination with COVID-19. Different clinical stages with variable clinical manifestations characterize the disease. Some of the symptoms carry a greater risk of complications than others. Postherpetic neuralgia, a chronic pain disease, is one of the most common possible complications. HZ vasculitis is linked to mortality and morbidity. gastrointestinal and renal complications have been reported. Early intervention with acyclovir or brivudine is the cornerstone of therapy. There are second-line treatments available. Management of pain is essential. Vaccination is a protective measure against shingles, and it can be administered alongside the COVID-19 vaccine. Healthy older individuals have access to two HZV vaccines for secondary prophylaxis: a live attenuated VZV vaccine and a recombinant adjuvanted VZV glycoprotein E subunit vaccine. A fully Covid-19 vaccinated patient was treated for Shingles which he received after he recovered from Covid-19. Our case study and recent research indicate a link between COVID-19 and shingles.

References

  1. Maria-Teresa Fernandez-Figueras. “Dermatopathology of COVID-19 infection and vaccination”. Pathology (Heidelb) 43.Suppl 1 (2022): 114-118.
  2. Feinandez-Lazaio D and Gaiiosa M. “Identification, Mechanism, and ľíeatment of Skin Lesions in COVID-19: A Review”. Viruses 13.10 (2021): 1916.
  3.  JM Carrascosa., et al. “Cutaneous Manifestations in the Context of SARS-CoV-2 Infection (COVID-19)”. Actas Deímosifiliogí (Engl Ed) 111.9 (2020): 734-742.
  4. Puri P., et al. “COVID-19 Rekindling Herpes Zoster in an Immunocompetent Patient”. Cureus 13.9 (2021): e18049.
  5. Tartari F., et al. “Herpes zoster in COVID-19-positive patients”. Int J Dermatol. 59 (2020): 1028-1029.
  6. Merad M and Martin JC. “Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages”. Nat Rev Immunol 20 (2020): 355-362.
  7. WHO Coronavirus (COVID-19) Dashboard (2021). https://covid19.who.int/
  8. Clinical Overview of Herpes Zoster (Shingles) | CDC (2021). https://www.cdc.gov/shingles/hcp/clinical-overview.html
  9. Weiss SR and Leibowitz JL. “Coronavirus pathogenesis”. Adv Virus Res 81 (2011): 85-164.
  10. Drosten C., et al. “Identification of a novel coronavirus in patients with severe acute respiratory syndrome”. N Engl J Med 348 (2003): 1967-1976.
  11. Mehta DN, Thakkar B and Asrani M. “Herpes zoster of orofacial region: a review”. Nat J Integr Res Med 4 (2013): 112-116.
  12. Thomas SL and Hall AJ. “What does epidemiology tell us about risk factors for herpes zoster?”. Lancet Infect Dis 4 (2004): 26-33.
  13. Xu B., et al. “Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China”. J Infect 81 (2020): e51-e60.
  14. Walter R., et al. “Reactivation of herpesvirus infections after vaccinations?”. Lancet 353 (1999): 810.
  15. Ruder H., et al. “Decreased alloreactivity after vaccination against hepatitis B”. Transplantation 59 (1995): 1339-1342.
  16. Eid E., et al. “Herpes zoster emergence following mRNA COVID-19 vaccine”. J Med Virol 93 (2021): 5231-5232.
  17. Tartari F., et al. “Herpes zoster in COVID-19-positive patients”. Int J Dermatol 59 (2020): 1028-1029.
  18. Sampathkumar P, Drage LA and Martin DP. “Herpes zoster (shingles) and postherpetic neuralgia”. Mayo Clin Proc 84 (2009): 274-280.
  19. Furer V., et al. “Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series”. Rheumatology (2021).
  20. Martinez E., et al. “High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors”. Clin Infect Dis 27 (1998): 1510-1513.